PMC:7212965 / 83477-83973 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T198","span":{"begin":259,"end":264},"obj":"Body_part"},{"id":"T199","span":{"begin":301,"end":312},"obj":"Body_part"}],"attributes":[{"id":"A198","pred":"fma_id","subj":"T198","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A199","pred":"fma_id","subj":"T199","obj":"http://purl.org/sig/ont/fma/fma55670"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T162","span":{"begin":259,"end":264},"obj":"Body_part"},{"id":"T163","span":{"begin":307,"end":312},"obj":"Body_part"}],"attributes":[{"id":"A162","pred":"uberon_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A163","pred":"uberon_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T392","span":{"begin":194,"end":202},"obj":"Disease"},{"id":"T393","span":{"begin":285,"end":294},"obj":"Disease"},{"id":"T394","span":{"begin":361,"end":369},"obj":"Disease"}],"attributes":[{"id":"A392","pred":"mondo_id","subj":"T392","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A393","pred":"mondo_id","subj":"T393","obj":"http://purl.obolibrary.org/obo/MONDO_0005155"},{"id":"A394","pred":"mondo_id","subj":"T394","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T627","span":{"begin":71,"end":74},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T628","span":{"begin":245,"end":247},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T629","span":{"begin":259,"end":264},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T630","span":{"begin":259,"end":264},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T631","span":{"begin":307,"end":312},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T632","span":{"begin":456,"end":458},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T189","span":{"begin":409,"end":411},"obj":"Chemical"},{"id":"T190","span":{"begin":412,"end":415},"obj":"Chemical"},{"id":"T191","span":{"begin":464,"end":473},"obj":"Chemical"}],"attributes":[{"id":"A189","pred":"chebi_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A190","pred":"chebi_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A191","pred":"chebi_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T382","span":{"begin":285,"end":294},"obj":"Phenotype"},{"id":"T383","span":{"begin":361,"end":369},"obj":"Phenotype"},{"id":"T384","span":{"begin":371,"end":387},"obj":"Phenotype"},{"id":"T385","span":{"begin":393,"end":407},"obj":"Phenotype"}],"attributes":[{"id":"A382","pred":"hp_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/HP_0001394"},{"id":"A383","pred":"hp_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A384","pred":"hp_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A385","pred":"hp_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/HP_0002027"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T794","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"T795","span":{"begin":61,"end":94},"obj":"Sentence"},{"id":"T796","span":{"begin":95,"end":120},"obj":"Sentence"},{"id":"T797","span":{"begin":121,"end":178},"obj":"Sentence"},{"id":"T798","span":{"begin":179,"end":244},"obj":"Sentence"},{"id":"T799","span":{"begin":245,"end":279},"obj":"Sentence"},{"id":"T800","span":{"begin":280,"end":340},"obj":"Sentence"},{"id":"T801","span":{"begin":341,"end":496},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2270","span":{"begin":203,"end":211},"obj":"Species"}],"attributes":[{"id":"A2270","pred":"tao:has_database_id","subj":"2270","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" Arentz, 202075Evergreen Hospital (Kirkland)WashingtonDates: 2/20/2020-3/5/2020Last follow-up: 3/17/2020 n = 21Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.Inclusion: Critically ill COVID-19 patients.Age: m 70 y (range, 43–92 y)Sex: 48% femalesGI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplantDisease severity: 100% critically ill Diarrhea, nausea, vomiting, and abdominal pain: NR AST m 273 (range, 14-4432)ALT m 108 (range, 11-1414)Bilirubin m 0.6 (range, 0.2-1.1)"}